Insider Buying: Nautilus Biotechnology (NASDAQ:NAUT) CEO Purchases $65,250.00 in Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Sujal Patel acquired 25,000 shares of Nautilus Biotechnology stock in a transaction dated Wednesday, March 4th. The stock was purchased at an average price of $2.61 per share, with a total value of $65,250.00. Following the completion of the purchase, the chief executive officer directly owned 10,366,721 shares of the company’s stock, valued at $27,057,141.81. The trade was a 0.24% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nautilus Biotechnology Trading Up 1.2%

NASDAQ NAUT opened at $2.47 on Friday. Nautilus Biotechnology, Inc. has a 1 year low of $0.62 and a 1 year high of $3.08. The company has a fifty day simple moving average of $2.20 and a 200 day simple moving average of $1.64. The company has a market cap of $312.60 million, a P/E ratio of -5.26 and a beta of 1.45.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its earnings results on Thursday, February 26th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. Equities research analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current fiscal year.

Institutional Trading of Nautilus Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of NAUT. Virtu Financial LLC increased its holdings in shares of Nautilus Biotechnology by 19.6% during the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after purchasing an additional 3,849 shares during the period. Millennium Management LLC lifted its stake in shares of Nautilus Biotechnology by 5.4% in the fourth quarter. Millennium Management LLC now owns 1,019,996 shares of the company’s stock valued at $1,989,000 after buying an additional 52,448 shares during the period. Bridgeway Capital Management LLC lifted its stake in shares of Nautilus Biotechnology by 4.0% in the fourth quarter. Bridgeway Capital Management LLC now owns 130,000 shares of the company’s stock valued at $254,000 after buying an additional 5,000 shares during the period. Captrust Financial Advisors acquired a new stake in Nautilus Biotechnology during the fourth quarter worth about $66,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Nautilus Biotechnology during the fourth quarter worth about $204,000. 50.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Guggenheim lifted their price objective on Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Thursday, January 22nd. Finally, Wall Street Zen raised Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 18th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $4.00.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.